Suneet Agarwal

Suneet Agarwal, MD, PhD, is Associate Professor of Pediatrics at Harvard Medical School and Co-Program Leader for the Stem Cell Transplant Center at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. His work bridges clinical pediatrics, hematology-oncology, and translational research in bone marrow failure and telomere biology disorders.

• Medical School: Harvard Medical School, 2001
• Internship: Boston Children's Hospital, 2002
• Residency: Pediatrics, Boston Combined Residency Program (BCRP), 2003
• Fellowship: Pediatric Hematology-Oncology, Dana Farber Cancer Institute/Children's Hospital Boston, 2006

Dr. Agarwal’s research focuses on telomere biology disorders, mitochondrial DNA deletion disorders, and inherited bone marrow failure syndromes. He employs induced pluripotent stem cells (iPSCs), gene editing, and molecular techniques to model diseases and develop therapies, including small-molecule PAPD5 inhibitors for telomere restoration. His lab investigates nucleotide metabolism, telomere length control, and heteroplasmy dynamics in mitochondrial disorders.

His recent publications reveal a strong thematic focus on telomere regulation, stem cell biology, and hematopoietic transplantation. Key trends include the role of nucleotide salvage in telomere maintenance, molecular mechanisms of telomere disease, and clinical outcomes in stem cell transplant for myelodysplastic syndrome and telomere disorders. His work frequently appears in top-tier journals such as Nature Genetics, Cell Stem Cell, and Blood.

Scientific contributions include:

• Discovery of PAPD5 inhibitors that restore telomerase activity in patient stem cells
• Mechanistic insights into TERC and TERT variants in telomere diseases
• Characterization of liver and vascular complications in dyskeratosis congenita
• Development of iPSC models for rare genetic blood disorders

Dr. Agarwal leads a research lab at Dana-Farber/Boston Children's and is actively involved in mentoring and scientific innovation. He has not publicly listed specific advisees or awards, but his research program is supported by extensive publications and clinical leadership. He is not indicated to be part-time, retired, or deceased.

His laboratory, the Suneet Agarwal Lab, is dedicated to understanding the molecular basis of genetic blood disorders and developing regenerative and pharmacological therapies. The lab utilizes cutting-edge technologies including single-cell multi-omics, genome editing, and stem cell reprogramming to uncover disease mechanisms and therapeutic targets.